Descrizione del progetto
Uno sforzo innovativo per il trattamento delle ulcere del piede diabetico
Le ulcere del piede diabetico sono una complicanza considerevole del diabete e, ad oggi, una condizione clinica senza soluzione. Tali ulcere possono infatti comportare l’ospedalizzazione, l’amputazione dell’arto e persino la morte, con un alto tasso di recidiva. Il progetto APTADEGRAD, finanziato dall’UE, fornirà una potenziale soluzione sviluppando una nuova terapia basata su chimere che bersagliano i lisosomi basati su aptameri (LYTAC, lysosome-targeting chimaeras) per guarire le ulcere del piede diabetico. La terapia bersaglierà le proteine chiave responsabili della guarigione alterata delle ferite diabetiche, offrendo una riduzione controllata a seconda della dose di MMP-9, IL-1β e del suo recettore IL-1R1. In caso di esito positivo, questo progetto potrebbe offrire un potenziale trattamento per altri tipi di ferite croniche e patologie immunitarie, con conoscenze essenziali acquisite sui LYTAC per un futuro sviluppo farmaceutico.
Obiettivo
Diabetic foot ulcers (DFUs) a major complication of diabetes, occur in ~25% of patients, with a five-year recurrence rate of ~65% .
DFUs often end in hospitalization, with limb amputations in up to 60% of cases . DFU related mortality is 5% within twelve months, rising to 42% after five years. Despite high prevalence and its major impact on the quality of life, no effective treatment has been approved, so DFU remain a highly unmet clinical condition.
APTADEGRAD aims at obtaining in vivo proof-of-concept for a novel, first-in-class therapy using aptamer-based Lysosome Targeted Chimeras (LYTACs) to heal diabetic foot ulcers (DFUs). These LYTACs will target IL-1β, its receptor IL-1R1, and MMP-9 for degradation, proteins known to play a key role in impaired healing in diabetic wounds. Out hypothesis is that a) aptamer-based LYTACs MoA, may offer the potential to deliver a controlled, dose-dependent reduction of MMP9, IL-1b and its receptor IL-1R1, moderating the excessive DFU inflammatory response, while maintaining biologically beneficial levels of these proteins to promote healing and prevent infection; b) the simultaneous targeting of these relevant proteins will produce a synergetic effect in the inflammation cascade, providing superior efficacy outcomes.
Should the main objective of the project is achieved (i.e. show efficacy in animal models of DFU), we would be showing for the first time a potential therapy based on LYTACs, in this case in the context of diabetic ulcers, with potential applications in other types of chronic wound or immune pathologies. In addition to efficacy data, we will be gathering essential knowledge about LYTACs (toxicity, efficacy, mechanism of action, differences with other approaches such as blocking or inhibition which are essential for successful future translation of the novel concept of LYTAC in pharmaceutical development to clinical trials.
Campo scientifico
Programma(i)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Invito a presentare proposte
HORIZON-EIC-2022-PATHFINDEROPEN-01
Vedi altri progetti per questo bandoMeccanismo di finanziamento
EIC - EICCoordinatore
32980 OURENSE
Spagna
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.